Background:
KRAS inhibitors, including Sotorasib and Adagrasib, have expanded treatment options for patients with KRAS-mutated non small cell lung cancer (NSCLC). However, cardiovascular outcomes after KRAS inhibitor initiation remain poorly characterized.
Hypothesis:
We hypothesized that cardiovascular events...
Amal Youssef, Cecilia Villa Etchegoyen, Sherif Ahmed et al.· Circulation· 0 citations
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes across several cardiometabolic conditions, but their role in World Health Organization group 1 pulmonary arterial hypertension (PAH) remains uncertain. We conducted a retrospective, single-center cohort study of adults with group 1 PAH. Patients prescr...
Abdelrahman Hafez, Amal Youssef, Mohamed Nour et al.· Mayo Clinic Proceedings: Inn...· 0 citations
A higher RAR was associated with abnormal LVGLS, HF hospitalization, and all-cause mortality after adjustment for clinical risk factors, but the RAR did not provide discriminative value beyond its individual components.
Sherif Ahmed, K. Awad, Abdelrahman Hafez et al.· Journal of Personalized Medi...· 0 citations
Major adverse cardiovascular events (MACE) remain the leading cause of mortality worldwide. Opportunistic screening using routinely acquired clinical data offers a scalable approach for identifying high-risk individuals before acute events occur. Although chest X-rays (CXRs) capture latent cardiovascular biomarkers and...